
Wei Cao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7482272/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Comparative Transcriptional Analysis Identified Characteristic Genes and Patterns in HIV-Infected Immunological Non-Responders. Frontiers in Immunology, 2022, 13, 807890.	2.2	9
2	<scp>BMI</scp> changes and the risk of lung cancer in male neverâ€smokers: A prospective cohort study. Cancer Medicine, 2022, 11, 1336-1346.	1.3	8
3	Lung cancer risk prediction models based on pulmonary nodules: A systematic review. Thoracic Cancer, 2022, 13, 664-677.	0.8	16
4	One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study. Lancet Respiratory Medicine,the, 2022, 10, 378-391.	5.2	69
5	Comparison of Renal Function Biomarkers of Serum Creatinine and Cystatin C in HIV-Infected People on Dolutegravir-Containing Therapy. Infection and Drug Resistance, 2022, Volume 15, 1695-1706.	1.1	4
6	Combined multi-omics and network pharmacology approach reveals the role of Tripterygium Wilfordii Hook F in treating HIV immunological non-responders. Phytomedicine, 2022, 101, 154103.	2.3	7
7	<scp>HBV pgRNA</scp> profiles in Chinese <scp>HIV</scp> / <scp>HBV</scp> coinfected patients under pre―and posttreatment: a multicentre observational cohort study. Journal of Viral Hepatitis, 2022, , .	1.0	2
8	Pressure injury: A non-negligible comorbidity for critical Covid-19 patients. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2021, 74, 644-710.	0.5	7
9	Divergence between serum creatine and cystatin C in estimating glomerular filtration rate of critically ill COVID-19 patients. Renal Failure, 2021, 43, 1104-1114.	0.8	14
10	Pharmacodynamics of efavirenz 400 mg in treatment-naÃ ⁻ ve Chinese HIV-infected patients in a prospective cohort study. BMC Infectious Diseases, 2021, 21, 112.	1.3	4
11	Long-term trabecular bone score and bone mineral density changes in Chinese antiretroviral-treated HIV-infected individuals. Archives of Osteoporosis, 2021, 16, 41.	1.0	3
12	High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China. Frontiers in Immunology, 2021, 12, 627844.	2.2	40
13	Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chinese Medical Journal, 2021, 134, 783-791.	0.9	1,329
14	NaÃ ⁻ ve CD4+ cell counts significantly decay and high HIV RNA levels contribute to immunological progression in long-term non-progressors infected with HIV by blood products: a cohort study. BMC Immunology, 2021, 22, 36.	0.9	2
15	Therapeutic prediction of HIV-1 DNA decay: a multicenter longitudinal cohort study. BMC Infectious Diseases, 2021, 21, 592.	1.3	4
16	Changes in trabecular bone score and bone mineral density in Chinese HIV-Infected individuals after one year of antiretroviral therapy. Journal of Orthopaedic Translation, 2021, 29, 72-77.	1.9	6
17	Combination of Tripterygium Wilfordii Hook F With Antiretroviral Therapy Delayed Viral Rebound in A Patient of Acute HIV-1 Infection. Infectious Diseases & Immunity, 2021, 1, 108-114.	0.2	1
18	The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence. Frontiers in Immunology, 2021, 12, 677957.	2.2	6

Wei Cao

#	Article	IF	CITATIONS
19	Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients. Signal Transduction and Targeted Therapy, 2021, 6, 304.	7.1	26
20	HIV-Related Immune Activation and Inflammation: Current Understanding and Strategies. Journal of Immunology Research, 2021, 2021, 1-13.	0.9	58
21	Menstrual factors, reproductive history, and risk of lung cancer: a multi-center population-based cohort study in Chinese females. Translational Lung Cancer Research, 2021, 10, 3912-3928.	1.3	4
22	SARSâ€CoVâ€2 not found in pressure injury exudates from COVIDâ€19 patients. Journal of Cosmetic Dermatology, 2021, 20, 372-380.	0.8	4
23	Prolonged presence of viral nucleic acid in clinically recovered COVID-19 patients was not associated with effective infectiousness. Emerging Microbes and Infections, 2020, 9, 2315-2321.	3.0	21
24	High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects. Frontiers in Immunology, 2020, 11, 1660.	2.2	48
25	Neurological Manifestations in Critically III Patients With COVID-19: A Retrospective Study. Frontiers in Neurology, 2020, 11, 806.	1.1	61
26	Clinicopathological Features and Outcomes of Acute Kidney Injury in Critically Ill COVID-19 with Prolonged Disease Course: A Retrospective Cohort. Journal of the American Society of Nephrology: JASN, 2020, 31, 2205-2221.	3.0	86
27	Whole blood as an alternative to peripheral blood mononuclear cell for detection of total HIV-1 DNA. BMC Infectious Diseases, 2020, 20, 941.	1.3	2
28	A Chinese case series of Schnitzler syndrome and complete remission in one tocilizumab-treated patient. Clinical Rheumatology, 2020, 39, 3847-3852.	1.0	13
29	Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerging Microbes and Infections, 2020, 9, 727-732.	3.0	684
30	High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019. Open Forum Infectious Diseases, 2020, 7, ofaa102.	0.4	327
31	Antiphospholipid Antibodies in Critically III Patients With COVIDâ€19. Arthritis and Rheumatology, 2020, 72, 1998-2004.	2.9	135
32	Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. Journal of Thrombosis and Thrombolysis, 2020, 50, 580-586.	1.0	127
33	Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-naÃ ⁻ ve patients. Infectious Diseases of Poverty, 2020, 9, 75.	1.5	8
34	Optimizing Treatment for Adults with HIV/AIDS in China: Successes over Two Decades and Remaining Challenges. Current HIV/AIDS Reports, 2020, 17, 26-34.	1.1	83
35	Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. Emerging Microbes and Infections, 2020, 9, 194-206.	3.0	54
36	HIV-1 CRF01_AE subtype and HIV-1 DNA level among patients with chronic HIV-1 infection: a correlation study. BMC Infectious Diseases, 2020, 20, 66.	1.3	6

Wei Cao

#	Article	IF	CITATIONS
37	COVID-19: towards understanding of pathogenesis. Cell Research, 2020, 30, 367-369.	5.7	281
38	SARS-CoV-2 Is Not Detectable in the Vaginal Fluid of Women With Severe COVID-19 Infection. Clinical Infectious Diseases, 2020, 71, 813-817.	2.9	158
39	Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. New England Journal of Medicine, 2020, 382, e38.	13.9	1,824
40	Multiple food-borne trematodiases with profound systemic involvement: a case report and literature review. BMC Infectious Diseases, 2019, 19, 526.	1.3	6
41	Epidemiologic Features, Radiological Findings and Clinical Outcomes of 19 Patients with COVID-19 in a Single Center in Beijing, China . Chinese Medical Sciences Journal, 2019, 36, 1.	0.2	0
42	Socioâ€economic status and time trends associated with early <scp>ART</scp> initiation following primary <scp>HIV</scp> infection in Montreal, Canada: 1996 to 2015. Journal of the International AIDS Society, 2018, 21, e25034.	1.2	24
43	Elevation and persistence of CD8 Tâ€cells in HIV infection: the Achilles heel in the ART era. Journal of the International AIDS Society, 2016, 19, 20697.	1.2	84
44	HIV immunotherapy comes of age: implications for prevention, treatment and cure. Expert Review of Clinical Immunology, 2016, 12, 91-94.	1.3	10
45	Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts. Clinical Infectious Diseases, 2016, 62, 250-257.	2.9	68
46	Aging of immune system: immune signature from peripheral blood lymphocyte subsets in 1068 healthy adults. Aging, 2016, 8, 848-859.	1.4	117
47	CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIVâ€positive patients. Journal of the International AIDS Society, 2015, 18, 20052.	1.2	186
48	Overcoming the challenge of diagnosis of early HIV infection: a stepping stone to optimal patient management. Expert Review of Anti-Infective Therapy, 2015, 13, 1189-1193.	2.0	6
49	Clinical Relevance of Kynurenine Pathway in HIV/AIDS: An Immune Checkpoint at the Crossroads of Metabolism and Inflammation. AIDS Reviews, 2015, 17, 96-106.	0.5	42
50	Antiretroviral Therapy in Primary HIV-1 Infection: Influences on Immune Activation and Gut Mucosal Barrier Dysfunction. AIDS Reviews, 2015, 17, 135-46.	0.5	11
51	CD8+ T cell responses specific for hepatitis B virus core protein in patients with chronic hepatitis B virus infection. Journal of Clinical Virology, 2014, 61, 40-46.	1.6	7
52	Parallel decline of CD8+CD38+ lymphocytes and viremia in treated hepatitis B patients. World Journal of Gastroenterology, 2011, 17, 2191.	1.4	14
53	Four novel ULBP splice variants are ligands for human NKG2D. International Immunology, 2008, 20, 981-991.	1.8	26
54	RAET1E2, a Soluble Isoform of the UL16-binding Protein RAET1E Produced by Tumor Cells, Inhibits NKG2D-mediated NK Cytotoxicity. Journal of Biological Chemistry, 2007, 282, 18922-18928.	1.6	63

WEI CAO

#	Article	IF	CITATIONS
55	The recognition pattern of gamma-delta T cells. Frontiers in Bioscience - Landmark, 2005, 10, 2676.	3.0	14
56	UL16 binding proteins. Immunobiology, 2004, 209, 283-290.	0.8	22
57	Anticancer drug resistance of HeLa cells transfected with rat glutathione S-transferase pi gene. Biomedical and Environmental Sciences, 2003, 16, 157-62.	0.2	2